Review





Similar Products

gene exp pdgfb mm00440677 m1  (Thermo Fisher)
99
Thermo Fisher gene exp pdgfb mm00440677 m1
Gene Exp Pdgfb Mm00440677 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/Gene+Exp%2E+Pdgfb%2C+Mm00440677_m1/bio_rxiv__64898__2026__01__30__702567-202-25--1
Average 99 stars, based on 1 article reviews
gene exp pdgfb mm00440677 m1 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
pdgfb  (Genomics England)
86
Genomics England pdgfb
Pdgfb, supplied by Genomics England, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/pdgfb/10__1016_slash_j__isci__2026__116143-61-36-45
Average 86 stars, based on 1 article reviews
pdgfb - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
mouse platelet derived growth factor subunit b pdgfb elisa kit  (Wuhan Fine Biotech)
86
Wuhan Fine Biotech mouse platelet derived growth factor subunit b pdgfb elisa kit
Mouse Platelet Derived Growth Factor Subunit B Pdgfb Elisa Kit, supplied by Wuhan Fine Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/elisa+kit+mouse+testosterone/pm41857463-95-0-13
Average 86 stars, based on 1 article reviews
mouse platelet derived growth factor subunit b pdgfb elisa kit - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
pdgfb floxed mice  (Jackson Laboratory)
86
Jackson Laboratory pdgfb floxed mice
(A) Quantification of <t>Pdgfb</t> from total retina RNA was normalized to beta-actin , n=9-11 retinas from 9-11 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. (B) Quantification of Pdgfb from total retina RNA was normalized to gapdh , n=5-7 retinas from 5-7 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. ( C ) Images of anti-LEF1 stain of parental bEnd.3 cells and a stable population of bEnd.3 cells overexpressing LEF1, generated by lentiviral transduction and selection with puromycin. Scale bar 100 µm. ( D ) Quantification of Pdgfb from total RNA of bEnd.3 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test. ( E ) Quantification of Pdgfb from total RNA of stable bEnd.3-LEF1 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test.
Pdgfb Floxed Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/conditional+dicer+knockout+strain/bio_rxiv__64898__2026__03__13__711629-144-0-3
Average 86 stars, based on 1 article reviews
pdgfb floxed mice - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
pdgfb  (R&D Systems)
95
R&D Systems pdgfb
(A) Quantification of <t>Pdgfb</t> from total retina RNA was normalized to beta-actin , n=9-11 retinas from 9-11 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. (B) Quantification of Pdgfb from total retina RNA was normalized to gapdh , n=5-7 retinas from 5-7 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. ( C ) Images of anti-LEF1 stain of parental bEnd.3 cells and a stable population of bEnd.3 cells overexpressing LEF1, generated by lentiviral transduction and selection with puromycin. Scale bar 100 µm. ( D ) Quantification of Pdgfb from total RNA of bEnd.3 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test. ( E ) Quantification of Pdgfb from total RNA of stable bEnd.3-LEF1 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test.
Pdgfb, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/Human+PDGF-BB+Quantikine+ELISA+Kit/us12553903-314-23-45
Average 95 stars, based on 1 article reviews
pdgfb - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
anti pdgfb  (Servicebio Inc)
86
Servicebio Inc anti pdgfb
(A) Quantification of <t>Pdgfb</t> from total retina RNA was normalized to beta-actin , n=9-11 retinas from 9-11 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. (B) Quantification of Pdgfb from total retina RNA was normalized to gapdh , n=5-7 retinas from 5-7 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. ( C ) Images of anti-LEF1 stain of parental bEnd.3 cells and a stable population of bEnd.3 cells overexpressing LEF1, generated by lentiviral transduction and selection with puromycin. Scale bar 100 µm. ( D ) Quantification of Pdgfb from total RNA of bEnd.3 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test. ( E ) Quantification of Pdgfb from total RNA of stable bEnd.3-LEF1 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test.
Anti Pdgfb, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/anti+pdgfb/10__1016_slash_j__redox__2025__104002-63-28-29
Average 86 stars, based on 1 article reviews
anti pdgfb - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
gene exp pdgfb mm01298578 m1  (Thermo Fisher)
98
Thermo Fisher gene exp pdgfb mm01298578 m1
(A) Expression of the stem cell markers EpCAM and CD90 in the established mouse HCC cell line PP53-2. (B) Antitumor effect of control or anti-PD-L1 antibody (aPD-L1) and anti-VEGF-A antibody (aVEGF-A) combination therapy in a syngeneic mouse model. (C, D) Antitumor effect of sequential DC101 treatment after combination therapy in a syngeneic mouse model. (D-H) Relative gene expression in tumor tissue of control and DC101 treatment; Epcam (E), Afp (F), Cd34 (G), Pecam (H), <t>Pdgfb</t> (I). (J) Representative photomicrographs showing EpCAM-positive CSCs and CD34-positive ECs in syngeneic mouse tumors after treatment. Red: mouse EpCAM, green: mouse CD34, blue: DAPI. (K) Relative staining area of mouse EpCAM in tumor tissues. (L) Relative staining area of mouse CD34 in tumor tissues. (M) Relative cell-to-cell distances from mouse EpCAM-positive cells to mouse CD34-positive cells. (N) Representative glomerular images from mice treated with control, combination therapy, or DC101 following combination therapy. (O) Mean glomerular area in mice treated with control, combination therapy, or DC101 following combination therapy. (P) Serum creatinine levels in mice treated with control, combination therapy, or DC101 following combination therapy. ∗ P < .05.
Gene Exp Pdgfb Mm01298578 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/Gene+Exp%2E+Pdgfb%2C+Mm01298578_m1/pmc12546878-47-28-32
Average 98 stars, based on 1 article reviews
gene exp pdgfb mm01298578 m1 - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
anti pdgfb antibody  (Huabio Inc)
86
Huabio Inc anti pdgfb antibody
(A) Expression of the stem cell markers EpCAM and CD90 in the established mouse HCC cell line PP53-2. (B) Antitumor effect of control or anti-PD-L1 antibody (aPD-L1) and anti-VEGF-A antibody (aVEGF-A) combination therapy in a syngeneic mouse model. (C, D) Antitumor effect of sequential DC101 treatment after combination therapy in a syngeneic mouse model. (D-H) Relative gene expression in tumor tissue of control and DC101 treatment; Epcam (E), Afp (F), Cd34 (G), Pecam (H), <t>Pdgfb</t> (I). (J) Representative photomicrographs showing EpCAM-positive CSCs and CD34-positive ECs in syngeneic mouse tumors after treatment. Red: mouse EpCAM, green: mouse CD34, blue: DAPI. (K) Relative staining area of mouse EpCAM in tumor tissues. (L) Relative staining area of mouse CD34 in tumor tissues. (M) Relative cell-to-cell distances from mouse EpCAM-positive cells to mouse CD34-positive cells. (N) Representative glomerular images from mice treated with control, combination therapy, or DC101 following combination therapy. (O) Mean glomerular area in mice treated with control, combination therapy, or DC101 following combination therapy. (P) Serum creatinine levels in mice treated with control, combination therapy, or DC101 following combination therapy. ∗ P < .05.
Anti Pdgfb Antibody, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/anti+pdgfb/pm41324831-92-118-123
Average 86 stars, based on 1 article reviews
anti pdgfb antibody - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
b6j cg zbtb20tg pdgfb appswind 20lms mmjax  (Mutant Mouse Resource & Research Center)
86
Mutant Mouse Resource & Research Center b6j cg zbtb20tg pdgfb appswind 20lms mmjax
(A) Expression of the stem cell markers EpCAM and CD90 in the established mouse HCC cell line PP53-2. (B) Antitumor effect of control or anti-PD-L1 antibody (aPD-L1) and anti-VEGF-A antibody (aVEGF-A) combination therapy in a syngeneic mouse model. (C, D) Antitumor effect of sequential DC101 treatment after combination therapy in a syngeneic mouse model. (D-H) Relative gene expression in tumor tissue of control and DC101 treatment; Epcam (E), Afp (F), Cd34 (G), Pecam (H), <t>Pdgfb</t> (I). (J) Representative photomicrographs showing EpCAM-positive CSCs and CD34-positive ECs in syngeneic mouse tumors after treatment. Red: mouse EpCAM, green: mouse CD34, blue: DAPI. (K) Relative staining area of mouse EpCAM in tumor tissues. (L) Relative staining area of mouse CD34 in tumor tissues. (M) Relative cell-to-cell distances from mouse EpCAM-positive cells to mouse CD34-positive cells. (N) Representative glomerular images from mice treated with control, combination therapy, or DC101 following combination therapy. (O) Mean glomerular area in mice treated with control, combination therapy, or DC101 following combination therapy. (P) Serum creatinine levels in mice treated with control, combination therapy, or DC101 following combination therapy. ∗ P < .05.
B6j Cg Zbtb20tg Pdgfb Appswind 20lms Mmjax, supplied by Mutant Mouse Resource & Research Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pdgfb/adora2a+b6+cg+cre+fvb+kg139gsat+mmucd+tg/pm41233906-53-9-11
Average 86 stars, based on 1 article reviews
b6j cg zbtb20tg pdgfb appswind 20lms mmjax - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


(A) Quantification of Pdgfb from total retina RNA was normalized to beta-actin , n=9-11 retinas from 9-11 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. (B) Quantification of Pdgfb from total retina RNA was normalized to gapdh , n=5-7 retinas from 5-7 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. ( C ) Images of anti-LEF1 stain of parental bEnd.3 cells and a stable population of bEnd.3 cells overexpressing LEF1, generated by lentiviral transduction and selection with puromycin. Scale bar 100 µm. ( D ) Quantification of Pdgfb from total RNA of bEnd.3 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test. ( E ) Quantification of Pdgfb from total RNA of stable bEnd.3-LEF1 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test.

Journal: bioRxiv

Article Title: A FZD4/LRP5 agonist restores pericyte coverage and vascular integrity by increasing PDGFB signaling

doi: 10.64898/2026.03.13.711629

Figure Lengend Snippet: (A) Quantification of Pdgfb from total retina RNA was normalized to beta-actin , n=9-11 retinas from 9-11 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. (B) Quantification of Pdgfb from total retina RNA was normalized to gapdh , n=5-7 retinas from 5-7 mice per group. Average +/− SE is shown. *P < 0.05 by 1-way ANOVA with Tukey’s post hoc test. ( C ) Images of anti-LEF1 stain of parental bEnd.3 cells and a stable population of bEnd.3 cells overexpressing LEF1, generated by lentiviral transduction and selection with puromycin. Scale bar 100 µm. ( D ) Quantification of Pdgfb from total RNA of bEnd.3 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test. ( E ) Quantification of Pdgfb from total RNA of stable bEnd.3-LEF1 cells after treatment with vehicle or F4L5.13. 2 technical replicates per biological replicate were averaged, n=3 biological replicates. Average +/− SE is shown. *P < 0.05 by unpaired Student’s t-test.

Article Snippet: Pdgfb floxed mice (Jackson lab stock 017622) were backcrossed to C57BL/6J.

Techniques: Staining, Generated, Transduction, Selection

(A) Expression of the stem cell markers EpCAM and CD90 in the established mouse HCC cell line PP53-2. (B) Antitumor effect of control or anti-PD-L1 antibody (aPD-L1) and anti-VEGF-A antibody (aVEGF-A) combination therapy in a syngeneic mouse model. (C, D) Antitumor effect of sequential DC101 treatment after combination therapy in a syngeneic mouse model. (D-H) Relative gene expression in tumor tissue of control and DC101 treatment; Epcam (E), Afp (F), Cd34 (G), Pecam (H), Pdgfb (I). (J) Representative photomicrographs showing EpCAM-positive CSCs and CD34-positive ECs in syngeneic mouse tumors after treatment. Red: mouse EpCAM, green: mouse CD34, blue: DAPI. (K) Relative staining area of mouse EpCAM in tumor tissues. (L) Relative staining area of mouse CD34 in tumor tissues. (M) Relative cell-to-cell distances from mouse EpCAM-positive cells to mouse CD34-positive cells. (N) Representative glomerular images from mice treated with control, combination therapy, or DC101 following combination therapy. (O) Mean glomerular area in mice treated with control, combination therapy, or DC101 following combination therapy. (P) Serum creatinine levels in mice treated with control, combination therapy, or DC101 following combination therapy. ∗ P < .05.

Journal: Gastro Hep Advances

Article Title: Vascular Endothelial Growth Factor Receptor 2-Targeted Therapy Suppresses the Progression of Alpha-Fetoprotein-Positive Hepatocellular Carcinoma After Combination Therapy With Anti–Programmed Death-Ligand 1 and Anti–Vascular Endothelial Growth Factor-A Antibodies

doi: 10.1016/j.gastha.2025.100778

Figure Lengend Snippet: (A) Expression of the stem cell markers EpCAM and CD90 in the established mouse HCC cell line PP53-2. (B) Antitumor effect of control or anti-PD-L1 antibody (aPD-L1) and anti-VEGF-A antibody (aVEGF-A) combination therapy in a syngeneic mouse model. (C, D) Antitumor effect of sequential DC101 treatment after combination therapy in a syngeneic mouse model. (D-H) Relative gene expression in tumor tissue of control and DC101 treatment; Epcam (E), Afp (F), Cd34 (G), Pecam (H), Pdgfb (I). (J) Representative photomicrographs showing EpCAM-positive CSCs and CD34-positive ECs in syngeneic mouse tumors after treatment. Red: mouse EpCAM, green: mouse CD34, blue: DAPI. (K) Relative staining area of mouse EpCAM in tumor tissues. (L) Relative staining area of mouse CD34 in tumor tissues. (M) Relative cell-to-cell distances from mouse EpCAM-positive cells to mouse CD34-positive cells. (N) Representative glomerular images from mice treated with control, combination therapy, or DC101 following combination therapy. (O) Mean glomerular area in mice treated with control, combination therapy, or DC101 following combination therapy. (P) Serum creatinine levels in mice treated with control, combination therapy, or DC101 following combination therapy. ∗ P < .05.

Article Snippet: Quantitative PCR probes for EpCAM (Hs00158980_m1), AFP (Hs00173490_m1), VEGFA (Hs00900055_m1), VEGFB (Hs00173634_m1), VEGFC (Hs01099203_m1), FLT1 (Hs01052935_m1), KDR (Hs00911700_m1), Epcam (Mm00493214_m1), Afp (Mm00431715_m1), Cd34 (Mm00519283_m1), Pecam1 (Mm00476702_m1), and Pdgfb (Mm01298578_m1) were procured from Applied Biosystems (Foster City, CA).

Techniques: Expressing, Control, Gene Expression, Staining